黑素瘤免疫检查点抑制剂治疗相关的生物标志物研究进展

doi:10.35541/cjd.20210259

中华皮肤科杂志 ›› 2023, Vol. 56 ›› Issue (3): 278-283.doi: 10.35541/cjd.20210259

黑素瘤免疫检查点抑制剂治疗相关的生物标志物研究进展

杨永婷¹ 李婷婷² 康晓静²

¹新疆医科大学研究生学院，乌鲁木齐 830054；²新疆维吾尔自治区人民医院皮肤性病科新疆皮肤病临床医学研究中心新疆皮肤病研究重点实验室（XJYS1707），乌鲁木齐 830001

收稿日期:2021-03-26 修回日期:2021-10-22 发布日期:2023-03-06
通讯作者: 康晓静 E-mail:drkangxj666@163.com
基金资助:
新疆维吾尔自治区重点研发计划项目（2021B03001-1）

Biomarkers related to the treatment of melanoma with immune checkpoint inhibitors

Yang Yongting¹, Li Tingting², Kang Xiaojing²

¹Graduate School of Xinjiang Medical University, Urumqi 830054, China; ²Department of Dermatology and Venereology, People′s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Clinical Research Center for Dermatologic Diseases, Xinjiang Key Laboratory of Dermatology Research（XJYS1707）, Urumqi 830001, China

Received:2021-03-26 Revised:2021-10-22 Published:2023-03-06
Contact: Kang Xiaojing E-mail:drkangxj666@163.com
Supported by:
Xinjiang Uygur Autonomous Region Key R&D Program（2021B03001-1）

摘要/Abstract

摘要： 【摘要】近年来免疫检查点抑制剂在黑素瘤的治疗中取得了突破性的进展。但是只有一小部分患者对免疫治疗有持久反应，且随着联合用药的出现，免疫相关不良事件的风险和耐药性也在增加。本文对黑素瘤免疫检查点抑制剂疗效标志物的研究进展作一综述，期望通过精准的预测标志物来筛选免疫治疗的获益人群，指导个体化临床治疗，降低耐药性及不良反应。

关键词: 痣和黑素瘤, 肿瘤微环境, 免疫检查点抑制剂, 肿瘤突变负荷, 外周血标志物, 肠道微生物菌群

Abstract: 【Abstract】 Recently, great breakthroughs have been made in immune checkpoint inhibitors for the treatment of melanoma. However, only a small proportion of patients show a long-lasting response to immunotherapy, and risks of immune-related adverse events and drug resistance have been also increasing along with the emergence of combination treatment. This review summarizes biomarkers related to the efficacy of immune checkpoint inhibitors in the treatment of melanoma, aiming to predict and screen out patients who may benefit from immunotherapy, guide individualized clinical treatment, and reduce the occurrence of drug resistance and adverse reactions.

Key words: Nevi and melanoma, Tumor microenvironment, Immune checkpoint inhibitors, Tumor mutation burden, Peripheral blood biomarkers, Gut microbiota

杨永婷李婷婷康晓静. 黑素瘤免疫检查点抑制剂治疗相关的生物标志物研究进展[J]. 中华皮肤科杂志, 2023,56(3):278-283. doi:10.35541/cjd.20210259

Yang Yongting, Li Tingting, Kang Xiaojing. Biomarkers related to the treatment of melanoma with immune checkpoint inhibitors[J]. Chinese Journal of Dermatology, 2023, 56(3): 278-283.doi:10.35541/cjd.20210259

参考文献 45

［1］	Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy［J］. Nat Rev Cancer, 2019,19（3）:133⁃150. doi: 10.1038/s41568⁃019⁃0116⁃x.
［2］	Kasakovski D, Skrygan M, Gambichler T, et al. Advances in targeting cutaneous melanoma［J］. Cancers （Basel）, 2021,13（9）:2090. doi: 10.3390/cancers13092090.
［3］	Hamid O, Robert C, Daud A, et al. Five⁃year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE⁃001［J］. Ann Oncol, 2019,30（4）:582⁃588. doi: 10.1093/annonc/mdz011.
［4］	Larkin J, Chiarion⁃Sileni V, Gonzalez R, et al. Five⁃year survival with combined nivolumab and ipilimumab in advanced melanoma［J］. N Engl J Med, 2019,381（16）:1535⁃1546. doi: 10.1056/NEJMoa1910836.
［5］	Larkin J, Chiarion⁃Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma［J］. N Engl J Med, 2015,373（1）:23⁃34. doi: 10.1056/NEJMoa1504030.
［6］	Rodríguez⁃Cerdeira C, Carnero Gregorio M, López⁃Barcenas A, et al. Advances in immunotherapy for melanoma: a comprehensive review［J］. Mediators Inflamm, 2017,2017:3264217. doi: 10.1155/2017/3264217.
［7］	Barrueto L, Caminero F, Cash L, et al. Resistance to checkpoint inhibition in cancer immunotherapy［J］. Transl Oncol, 2020,13（3）:100738. doi: 10.1016/j.tranon.2019.12.010.
［8］	Luke JJ, Flaherty KT, Ribas A, et al. Targeted agents and immunotherapies: optimizing outcomes in melanoma［J］. Nat Rev Clin Oncol, 2017,14（8）:463⁃482. doi: 10.1038/nrclinonc. 2017.43.
［9］	Olbryt M, Rajczykowski M, Widłak W. Biological factors behind melanoma response to immune checkpoint inhibitors［J］. Int J Mol Sci, 2020,21（11）:4071. doi: 10.3390/ijms21114071.
［10］	Espinosa E, Márquez⁃Rodas I, Soria A, et al. Predictive factors of response to immunotherapy⁃a review from the Spanish Melanoma Group （GEM）［J］. Ann Transl Med, 2017,5（19）:389. doi: 10.21037/atm.2017.08.10.
［11］	Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti⁃PD⁃1 antibody in cancer［J］. N Engl J Med, 2012,366（26）:2443⁃2454. doi: 10.1056/NEJMoa1200690.
［12］	Rozeman EA, Dekker T, Haanen J, et al. Advanced melanoma: current treatment options, biomarkers, and future perspectives［J］. Am J Clin Dermatol, 2018,19（3）:303⁃317. doi: 10.1007/s40257⁃017⁃0325⁃6.
［13］	Patel SP, Kurzrock R. PD⁃L1 expression as a predictive biomarker in cancer immunotherapy［J］. Mol Cancer Ther, 2015,14（4）:847⁃856. doi: 10.1158/1535⁃7163.MCT⁃14⁃0983.
［14］	Mansfield AS, Murphy SJ, Peikert T, et al. Heterogeneity of programmed cell death ligand 1 expression in multifocal lung cancer［J］. Clin Cancer Res, 2016,22（9）:2177⁃2182. doi: 10. 1158/1078⁃0432.CCR⁃15⁃2246.
［15］	Hellmann MD, Nathanson T, Rizvi H, et al. Genomic features of response to combination immunotherapy in patients with advanced non⁃small⁃cell lung cancer［J］. Cancer Cell, 2018,33（5）:843⁃852.e4. doi: 10.1016/j.ccell.2018.03.018.
［16］	Sade⁃Feldman M, Yizhak K, Bjorgaard SL, et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma［J］. Cell, 2018,175（4）:998⁃1013.e20. doi: 10.1016/j.cell.2018.10.038.
［17］	Tumeh PC, Harview CL, Yearley JH, et al. PD⁃1 blockade induces responses by inhibiting adaptive immune resistance［J］. Nature, 2014,515（7528）:568⁃571. doi: 10.1038/nature13954.
［18］	Riaz N, Havel JJ, Makarov V, et al. Tumor and microenvironment evolution during immunotherapy with nivolumab［J］. Cell, 2017,171（4）:934⁃949.e16. doi: 10.1016/j.cell.2017.09.028.
［19］	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA⁃4 blockade in melanoma［J］. N Engl J Med, 2014,371（23）:2189⁃2199. doi: 10.1056/NEJMoa1406498.
［20］	Fabrizio DA, George TJ Jr, Dunne RF, et al. Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition［J］. J Gastrointest Oncol, 2018,9（4）:610⁃617. doi: 10.21037/jgo.2018.05.06.
［21］	Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD⁃1 blockade［J］. Science, 2017,357（6349）:409⁃413. doi: 10.1126/science.aan6733.
［22］	Liebl MC, Hofmann TG. Identification of responders to immune checkpoint therapy: which biomarkers have the highest value?［J］. J Eur Acad Dermatol Venereol, 2019,33 Suppl 8:52⁃56. doi: 10.1111/jdv.15992.
［23］	Meyers DE, Banerji S. Biomarkers of immune checkpoint inhibitor efficacy in cancer［J］. Curr Oncol, 2020,27（Suppl 2）:S106⁃S114. doi: 10.3747/co.27.5549.
［24］	Amann VC, Ramelyte E, Thurneysen S, et al. Developments in targeted therapy in melanoma［J］. Eur J Surg Oncol, 2017,43（3）:581⁃593. doi: 10.1016/j.ejso.2016.10.014.
［25］	Van Allen EM, Miao D, Schilling B, et al. Genomic correlates of response to CTLA⁃4 blockade in metastatic melanoma［J］. Science, 2015,350（6257）:207⁃211. doi: 10.1126/science.aad0095.
［26］	McGranahan N, Furness AJ, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade［J］. Science, 2016,351（6280）:1463⁃1469. doi: 10.1126/science.aaf1490.
［27］	Duan F, Duitama J, Al Seesi S, et al. Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity［J］. J Exp Med, 2014,211（11）:2231⁃2248. doi: 10.1084/jem.20141308.
［28］	Łuksza M, Riaz N, Makarov V, et al. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy［J］. Nature, 2017,551（7681）:517⁃520. doi: 10.1038/nature24473.
［29］	Kim S, Kim HS, Kim E, et al. Neopepsee: accurate genome⁃level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information［J］. Ann Oncol, 2018,29（4）:1030⁃1036. doi: 10.1093/annonc/mdy022.
［30］	Davoli T, Uno H, Wooten EC, et al. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy［J］. Science, 2017,355（6322）:eaaf8399. doi: 10.1126/science.aaf8399.
［31］	Leonardi GC, Falzone L, Salemi R, et al. Cutaneous melanoma: from pathogenesis to therapy （Review）［J］. Int J Oncol, 2018,52（4）:1071⁃1080. doi: 10.3892/ijo.2018.4287.
［32］	Lee JH, Long GV, Boyd S, et al. Circulating tumour DNA predicts response to anti⁃PD1 antibodies in metastatic melanoma［J］. Ann Oncol, 2017,28（5）:1130⁃1136. doi: 10.1093/annonc/mdx026.
［33］	Cabel L, Riva F, Servois V, et al. Circulating tumor DNA changes for early monitoring of anti⁃PD1 immunotherapy: a proof⁃of⁃concept study［J］. Ann Oncol, 2017,28（8）:1996⁃2001. doi: 10.1093/annonc/mdx212.
［34］	Lee JH, Long GV, Menzies AM, et al. Association between circulating tumor dna and pseudoprogression in patients with metastatic melanoma treated with anti⁃programmed cell death 1 antibodies［J］. JAMA Oncol, 2018,4（5）:717⁃721. doi: 10.1001/jamaoncol.2017.5332.
［35］	Tomela K, Pietrzak B, Schmidt M, et al. The tumor and host immune signature, and the gut microbiota as predictive biomarkers for immune checkpoint inhibitor response in melanoma patients［J］. Life （Basel）, 2020,10（10）. doi: 10.3390/life10100219.
［36］	Jiang H, Gebhardt C, Umansky L, et al. Elevated chronic inflammatory factors and myeloid⁃derived suppressor cells indicate poor prognosis in advanced melanoma patients［J］. Int J Cancer, 2015,136（10）:2352⁃2360. doi: 10.1002/ijc.29297.
［37］	Gebhardt C, Sevko A, Jiang H, et al. Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab［J］. Clin Cancer Res, 2015,21（24）:5453⁃5459. doi: 10.1158/1078⁃0432.CCR⁃15⁃0676.
［38］	Weber J, Gibney G, Kudchadkar R, et al. Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab［J］. Cancer Immunol Res, 2016,4（4）:345⁃353. doi: 10.1158/2326⁃6066.CIR⁃15⁃0193.
［39］	Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD⁃1⁃based immunotherapy against epithelial tumors［J］. Science, 2018,359（6371）:91⁃97. doi: 10. 1126/science.aan3706.
［40］	Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA⁃4 blockade relies on the gut microbiota［J］. Science, 2015,350（6264）:1079⁃1084. doi: 10.1126/science.aad1329.
［41］	Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti⁃PD⁃1 immunotherapy in melanoma patients［J］. Science, 2018,359（6371）:97⁃103. doi: 10.1126/science.aan4236.
［42］	Peters BA, Wilson M, Moran U, et al. Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients［J］. Genome Med, 2019,11（1）:61. doi: 10.1186/s13073⁃019⁃0672⁃4.
［43］	Frankel AE, Coughlin LA, Kim J, et al. Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients［J］. Neoplasia, 2017,19（10）:848⁃855. doi: 10.1016/j.neo.2017.08.004.
［44］	Coutzac C, Jouniaux JM, Paci A, et al. Systemic short chain fatty acids limit antitumor effect of CTLA⁃4 blockade in hosts with cancer［J］. Nat Commun, 2020,11（1）:2168. doi: 10.1038/s41467⁃ 020⁃16079⁃x.
［45］	Nomura M, Nagatomo R, Doi K, et al. Association of short⁃chain fatty acids in the gut microbiome with clinical response to treatment with nivolumab or pembrolizumab in patients with solid cancer tumors［J］. JAMA Netw Open, 2020,3（4）:e202895. doi: 10.1001/jamanetworkopen.2020.2895.

[1]	王媛丽刘玲孙中斌李凯. 临床误诊为黑素瘤的其他疾病141例分析[J]. 中华皮肤科杂志, 2023, 56(3): 244-246.
[2]	李婷婷康晓静. 肠道菌群与黑素瘤免疫检查点抑制剂治疗的研究进展[J]. 中华皮肤科杂志, 2023, 56(2): 177-180.
[3]	郑娜娜曾荣, 陶盈凯李岷, . 环状RNA与皮肤肿瘤相关性研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20210893-e20210893.
[4]	杨爱民成将伟黄嘉诚岑瑛陈俊杰. Merkel细胞癌治疗新进展[J]. 中华皮肤科杂志, 2023, 0(2): 20210536-e20210536.
[5]	张宁李舒李敬. 免疫检查点抑制剂和靶向药物辅助治疗可切除黑素瘤疗效的网状Meta分析[J]. 中华皮肤科杂志, 2022, 55(7): 603-609.
[6]	施雁庭黎皓郑捷曹华. 程序性细胞死亡蛋白1及其配体通路在特发性炎症性肌病中的研究进展[J]. 中华皮肤科杂志, 2022, 55(7): 633-636.
[7]	高妮刘宇王雷刘玲高天文李凯. 孤立性真皮黑素瘤5例临床及组织病理分析[J]. 中华皮肤科杂志, 2022, 55(5): 408-410.
[8]	邹美熔汪盛. 免疫检查点抑制剂所致皮肤免疫相关不良反应的研究进展[J]. 中华皮肤科杂志, 2022, 55(11): 1026-1030.
[9]	李婷婷关猛猛赵娟康晓静. 单细胞转录组测序在黑素瘤研究中的应用[J]. 中华皮肤科杂志, 2022, 0(1): 20210191-e20210191.
[10]	曹蒙洪安澜王焱方方. 儿童黑素瘤临床研究进展[J]. 中华皮肤科杂志, 2022, 0(1): 20210158-e20210158.
[11]	董栋, 刘天一. 细胞代谢与皮肤恶性黑素瘤转移的研究进展[J]. 中华皮肤科杂志, 2022, 0(1): 20210023-e20210023.
[12]	李嘉祺叶枫鞠强. 表皮葡萄球菌共生性稳态与皮肤疾病[J]. 中华皮肤科杂志, 2022, 0(1): 20210072-e20210072.
[13]	王冠钰王艺萌李薇薇张春雷. 复发/难治性皮肤T细胞淋巴瘤的非化疗药物新选择[J]. 中华皮肤科杂志, 2022, 0(1): 20210850-e20210850.
[14]	张聪聪陈浩. 铁死亡在黑素瘤中的研究进展[J]. 中华皮肤科杂志, 2022, 0(1): 20220135-e20220135.
[15]	郭伟赵涛郭伟楠马翠玲高天文赵建红李冰. 早期甲黑素瘤115例手术治疗方案和预后回顾分析[J]. 中华皮肤科杂志, 2021, 54(9): 777-784.

黑素瘤免疫检查点抑制剂治疗相关的生物标志物研究进展

Biomarkers related to the treatment of melanoma with immune checkpoint inhibitors

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 45

相关文章 15

Metrics

本文评价

推荐阅读 10